Vivesto AB (ST:VIVE) — Market Cap & Net Worth
Market Cap & Net Worth: Vivesto AB (VIVE)
Vivesto AB (ST:VIVE) has a market capitalization of $10.37 Million (Skr96.32 Million) as of August 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26939 globally and #584 in its home market, demonstrating a -1.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vivesto AB's stock price Skr8.70 by its total outstanding shares 11071369 (11.07 Million). See Vivesto AB capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Vivesto AB Market Cap History: 2015 to 2026
Vivesto AB's market capitalization history from 2015 to 2026. Data shows change from $7.93 Million to $10.37 Million (-1.78% CAGR).
Vivesto AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vivesto AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.51x
Vivesto AB's market cap is 0.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.85 Million | $172.00K | -$160.24 Million | 39.83x | N/A |
| 2017 | $2.06 Million | $3.17 Million | -$118.01 Million | 0.65x | N/A |
| 2018 | $7.18 Million | $1.98 Million | -$171.02 Million | 3.63x | N/A |
| 2019 | $4.93 Million | $201.84 Million | -$10.53 Million | 0.02x | N/A |
| 2020 | $4.91 Million | $201.84 Million | -$10.53 Million | 0.02x | N/A |
| 2021 | $3.13 Million | $26.19 Million | -$138.94 Million | 0.12x | N/A |
| 2022 | $517.09K | $1.01 Million | -$367.03 Million | 0.51x | N/A |
Competitor Companies of VIVE by Market Capitalization
Companies near Vivesto AB in the global market cap rankings as of August 5, 2026.
Key companies related to Vivesto AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Vivesto AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Vivesto AB's market cap moved from $7.93 Million to $ 10.37 Million, with a yearly change of -1.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr10.37 Million | +6344.44% |
| 2025 | Skr160.85K | -53.45% |
| 2024 | Skr345.52K | -28.83% |
| 2023 | Skr485.52K | -6.11% |
| 2022 | Skr517.09K | -83.45% |
| 2021 | Skr3.13 Million | -36.33% |
| 2020 | Skr4.91 Million | -0.48% |
| 2019 | Skr4.93 Million | -31.31% |
| 2018 | Skr7.18 Million | +249.23% |
| 2017 | Skr2.06 Million | -69.99% |
| 2016 | Skr6.85 Million | -13.61% |
| 2015 | Skr7.93 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Vivesto AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.37 Million USD |
| MoneyControl | $10.37 Million USD |
| MarketWatch | $10.37 Million USD |
| marketcap.company | $10.37 Million USD |
| Reuters | $10.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantri… Read more